However, Il-6 levels were significantly reduced by adding JEKHT to the treatment regimen in malignant tumors (P = 0.03) that also expressed significantly higher levels of Il-6 than benign tumors (P = 0.04) (Fig. 5B). The gene discussed is IL6; the disease is benign neoplasm.